Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind,…

By F. Raal, R. Santos, D. Blom, D. Marais, M. Charng, W. Cromwell, R. Lachmann, D. Gaudet, J. Tan, S. Chasan-Taber and 3 more. The Lancet, 2010

839 citations recorded by the source corpus.

Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/f31663d8e75bfdeb2e4d19ad379509289709cfc5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. S. Gidding

Citations in the corpus

• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011, background): “Recently a number of promising new drugs have reached phase III in clinical trials and have been reported to lower LDL-C effectively in severe hypercholesterolaemias, including microsomal transfer protein (MTP) inhibitors,(117) thyroid hormone mimetics with liver selectivity,(118) and oligonucleotid”
• The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. (2015, background): “mended LDL-C target in the vast majority of homozygous FH patients.(160) Lomitapide, an oral inhibitor of microsomal trans-”